Novel strategies for development of hemorrhagic fever arenavirus live-attenuated vaccines

Introduction: Several arenaviruses, chiefly Lassa virus (LASV), cause hemorrhagic fever (HF) disease in humans and pose significant public health problems in their endemic regions. Moreover, HF arenaviruses represent credible biodefense threats. There are not FDA-approved arenavirus vaccines and cur...

Full description

Saved in:
Bibliographic Details
Published in:Expert review of vaccines Vol. 15; no. 9; pp. 1113 - 1121
Main Authors: Martinez-Sobrido, Luis, de la Torre, Juan Carlos
Format: Journal Article
Language:English
Published: England Taylor & Francis 01.09.2016
Subjects:
Animals
Arenaviridae Infections - prevention & control
Arenaviridae Infections - virology
arenavirus
Arenavirus - immunology
Candid1
codon deoptimization
Drug Discovery - trends
Drug Evaluation, Preclinical
Hemorrhagic Fevers, Viral - prevention & control
Hemorrhagic Fevers, Viral - virology
Humans
Junin virus (JUNV)
Lassa virus (LASV)
live-attenuated vaccine
reverse genetics
tri-segmented arenavirus
Vaccines, Attenuated - immunology
Vaccines, Attenuated - isolation & purification
Viral hemorrhagic fever
Viral Vaccines - immunology
Viral Vaccines - isolation & purification
arenavirus
reverse genetics
Junin virus (JUNV)
Candid1
Lassa virus (LASV)
codon deoptimization
tri-segmented arenavirus
Viral hemorrhagic fever
live-attenuated vaccine
ISSN:1476-0584, 1744-8395, 1744-8395
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: Several arenaviruses, chiefly Lassa virus (LASV), cause hemorrhagic fever (HF) disease in humans and pose significant public health problems in their endemic regions. Moreover, HF arenaviruses represent credible biodefense threats. There are not FDA-approved arenavirus vaccines and current anti-arenaviral therapy is limited to an off-label use of ribavirin that is only partially effective. Areas covered: Live-attenuated vaccines (LAV) represent the most feasible approach to control HF arenaviruses within their endemic regions. Different platforms, including recombinant viral vectors expressing LASV antigens, and the use of attenuated reassortant arenaviruses, have been used to develop LAV candidates against LASV with promising results in animal models of LASV infection, but none of them has entered a clinical trial. These vaccine efforts have been the subject of recent reviews and will not be examined in this review, which is focused on new avenues for the development of safe and effective LAV to combat HF arenaviruses. Expert commentary: The development of arenavirus reverse genetics has provided investigators with a novel powerful approach to manipulate the genomes of HF arenaviruses, which has opened new avenues for the rapid development of safe and effective LAV to combat these human pathogens.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1476-0584
1744-8395
1744-8395
DOI:10.1080/14760584.2016.1182024